Javelin Pharmaceuticals
Javelin Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the research, development, and commercialization of products
About Javelin Pharmaceuticals
Javelin Pharmaceuticals, Inc. was a specialty pharmaceutical company established in 1998 by Fred Mermelstein to address unmet needs in the pain management market. Initially known as Intrac, the Cambridge, Massachusetts-based firm focused on applying proprietary technologies to develop novel drugs and enhance existing ones. The company's primary market was hospital-based pain management, targeting conditions such as post-operative, cancer, post-trauma, and procedural pain.
The company's lead product candidate was Dyloject, an injectable formulation of diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID). This product was developed as a non-opioid alternative for managing moderate-to-severe post-operative pain, a significant area of need given the adverse side effects associated with traditional opioids. Dyloject received marketing approval in the United Kingdom and was submitted for approval to the U.S. Food and Drug Administration (FDA). Javelin's pipeline also included other pain treatments in advanced clinical development, such as Ereska (intranasal ketamine) and Rylomine (intranasal morphine).
After a series of funding rounds, including a PIPE deal in 2005 and going public, Javelin's trajectory culminated in an acquisition. In 2010, after a bidding process that also involved Myriad Pharmaceuticals, Javelin entered into a definitive merger agreement with Hospira, Inc., a global specialty pharmaceutical company. Hospira acquired Javelin for approximately $145 million, viewing Dyloject as a strategic fit with its own portfolio, particularly its sedation agent Precedex, as both were marketed to anesthesiologists. The acquisition was completed in mid-2010, and Javelin became a wholly-owned subsidiary of Hospira, which itself was later acquired by Pfizer.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Dec 2009 | $95M | $95M | Myriad Genetics | — |
| GRANTOther financing | Jul 2006 | $750K | — | National Cancer Institute (NCI) | — |
Growth signals
Latest recorded traffic for Javelin Pharmaceuticals is 41K monthly website visits. Javelin Pharmaceuticals's team declined 18.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Javelin Pharmaceuticals in the Cambridge ecosystem
The Javelin Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Cancer Institute (NCI)
Series B and later1 investor entered at this stage
- WCWexford Capital
Other known investors1 additional known investor
Myriad Genetics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Javelin Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Javelin Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









